Outsourcing has become an established part of modern pharmaceutical manufacturing.
Drug developers may depend on Contract Manufacturing Organisations (CMOs), Contract Development and Manufacturing Organisations (CDMOs), testing laboratories, packaging specialists, logistics providers and raw-material suppliers spread across multiple countries.
The advantages are significant.
Outsourcing can provide specialist expertise, additional manufacturing capacity, access to advanced technologies and the ability to scale production without building entirely new internal infrastructure.
It can also create increasingly complex quality networks.
The central challenge for Quality Assurance is simple: activities can be outsourced, but responsibility for quality cannot simply be transferred.
Visibility Becomes a Quality Requirement
When manufacturing takes place internally, QA has relatively direct visibility of equipment, processes, personnel, documentation and deviations.
With outsourced manufacturing, that visibility becomes more complicated.
Quality teams may be relying on another company’s procedures, personnel, digital systems and quality culture.
This means supplier qualification cannot be treated as a procurement exercise.
Before appointing a manufacturing partner, organisations need to understand the provider’s technical capabilities, inspection history where available, quality-management system, deviation and CAPA processes, data-integrity controls, training arrangements and ability to manage the specific product.
The assessment should be based on risk.
A supplier manufacturing a critical sterile drug product should logically receive a different level of oversight from a supplier providing a comparatively low-risk non-critical service.
Quality Agreements Need to Work in Practice
A well-written quality agreement is one of the foundations of outsourced manufacturing.
It should clearly establish responsibilities for activities such as:
- deviations and investigations;
- CAPAs;
- change control;
- batch documentation;
- complaints;
- recalls;
- audits;
- testing;
- data retention;
- regulatory communication;
- subcontracting;
- product quality reviews; and
- escalation of significant quality events.
The European Medicines Agency’s GMP questions and answers reiterate expectations surrounding written contracts for outsourced manufacturing arrangements and the responsibilities of parties involved in the manufacturing and batch-certification chain.
However, agreements alone do not establish control.
A 50-page quality agreement provides limited protection if critical deviations are not escalated promptly or if a sponsor discovers major changes only during an annual review.
The working relationship behind the agreement matters just as much as the document itself.
Build Quality Governance Around the Relationship
Strong outsourced models typically require regular QA-to-QA communication.
Rather than contacting a CMO primarily when something has gone wrong, organisations should establish ongoing governance.
Useful quality indicators might include:
- deviation rates;
- investigation closure times;
- overdue CAPAs;
- right-first-time batch performance;
- environmental-monitoring trends where relevant;
- rejected batches;
- recurring laboratory investigations;
- audit findings; and
- change-control performance.
The objective should not be creating as many KPIs as possible.
Quality metrics should help identify deteriorating performance before it becomes a major compliance or supply problem.
ICH Q10 specifically includes management of outsourced activities and purchased materials within the pharmaceutical quality-system model. It places responsibility on pharmaceutical companies to have processes in place to assess suitability and performance of contracted parties and ensure responsibilities are defined.
Change Control Is a Particular Risk
One of the most important areas of outsourced QA is change management.
Manufacturing partners may replace equipment, introduce new analytical technology, modify suppliers, change manufacturing parameters or update software systems.
To the contractor, some of these may appear routine.
For the product owner, however, they could affect regulatory commitments, validated processes, critical quality attributes or comparability.
Quality agreements should therefore establish exactly which changes require prior approval, notification or assessment.
The sponsor also needs the internal expertise to evaluate the consequences.
This becomes particularly important for biological products, where changes in manufacturing can require sophisticated comparability assessments. ICH Q5E establishes principles for assessing whether manufacturing changes adversely affect product quality, safety or efficacy.
Watch the Entire Supply Chain
Outsourcing rarely ends with one CMO.
The CMO may itself rely on testing laboratories, raw-material suppliers, sterilisation providers or packaging contractors.
This creates a network rather than a simple customer-supplier relationship.
EMA guidance specifically addresses contractual chains and highlights the importance of clearly defining relevant entities and responsibilities within outsourced manufacturing arrangements.
QA therefore needs to know where critical activities actually occur.
Subcontracting should never turn important parts of the manufacturing process into blind spots.
Audits Remain Important, but They Are Not Enough
Supplier audits remain an essential oversight mechanism.
However, an audit every few years cannot provide continuous assurance.
A facility can perform extremely well during an audit and subsequently experience staffing problems, equipment issues, recurring deviations or deteriorating quality metrics.
QA oversight should therefore combine audits with ongoing performance monitoring, regular governance discussions, change control and investigation review.
Risk should determine the intensity of oversight.
Quality Culture Crosses Company Boundaries
Technical capabilities matter enormously when selecting a manufacturing partner, but quality culture can prove equally important.
Does the organisation openly escalate problems?
Are investigations designed to identify root causes or simply close records?
Does production regard QA as an obstacle or a partner?
Does management invest in preventive quality measures?
FDA’s evolving Quality Management Maturity programme illustrates the wider regulatory interest in quality practices that extend beyond baseline CGMP compliance. FDA describes mature quality management as supporting manufacturing performance, reliable supply and proactive continual improvement.
Those characteristics become particularly valuable when trusting another organisation with critical manufacturing operations.
Outsourcing Changes QA, It Does Not Reduce Its Importance
The growth of external manufacturing does not reduce the need for strong internal QA.
It changes where QA needs to focus.
Rather than overseeing every manufacturing activity directly, teams increasingly need expertise in supplier qualification, governance, auditing, quality agreements, risk management, data analysis and cross-organisational communication.
Outsourced networks can provide enormous strategic advantages to pharmaceutical companies.
But as those networks become larger and more international, maintaining control requires structured oversight.
The strongest outsourcing relationships are therefore not simply commercial arrangements.
They are quality partnerships built on transparency, clearly assigned responsibilities and a shared understanding that wherever manufacturing occurs, patient protection remains the ultimate objective.